About Omeros

To develop elegant solutions to complex problems, collaborative innovation is a necessity that we foster and celebrate. It’s not just part of the Omeros culture, it’s part of our fabric.

Who Is Omeros?

True innovation requires the right people, and that’s what we have at Omeros – smart, hard-working and creative individuals who collaborate and drive to achieve what has not yet been done. We see strength in diversity – diversity in thought, expertise and experience.

We have taken a similar approach in structuring our company. While many biotechs pursue a single therapeutic area or scientific platform, we are strategically building a deep and diverse pipeline of first-in-class small-molecule and antibody therapeutics. The strength of our scientific discoveries and exclusive intellectual property positions enable our pipeline programs to target highly promising receptors and enzymes that others have not been able to develop.

Although cutting across a wide and diverse range of disorders and therapeutic indications – some orphan, others large-market and many for which there are no approved treatments – all of our drugs on the market and in development target critical unmet needs to improve the lives of patients in meaningful ways.

Omeros areas of research

Omeros at a Glance

Founded in 1994

Based in Seattle, WA on Elliott Bay in Lower Queen Anne

Number of employees: 250, as of April 1, 2019

Fully vertically integrated with one commercial product and multiple late- and early-stage assets

Publicly traded on NASDAQ (OMER)

Company Milestones

Present
OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3% has been used in more than 600,000 ophthalmic procedures...and growing
2018
Narsoplimab receives Breakthrough Therapy designation from the FDA for high-risk HSCT-TMA
Narsoplimab receives Orphan Drug designation from the FDA for treatment of HSCT-TMA
Narsoplimab receives Orphan Medicinal Product designation from the EMA for treatment of HSCT-TMA
Narsoplimab receives Orphan Medicinal Product designation from the EMA for treatment of IgA nephropathy
OMS527 clinical studies are initiated
2017
Narsoplimab receives Breakthrough Therapy designation from the FDA for treatment of IgA nephropathy
Narsoplimab receives Orphan Drug designation from the FDA for treatment of IgA nephropathy
2015
Narsoplimab receives Fast Track designation from the FDA for treatment of aHUS
2014
OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3% receives FDA approval
2012
Omeros moves to new waterfront headquarters
2010
OMIDRIA clinical studies are initiated
Omeros enters funding agreements for our GPCR discovery program with Vulcan Inc. and Washington State Life Science Discovery Fund
Omeros establishes a charitable entity to fund nonprofit life sciences organizations in Washington State from GPCR proceeds
2009
Omeros completes IPO
2006
Omeros acquires nura
1994
Omeros is founded